Weight management · Phase 2
Mazdutide: US phase 2 weight study
What was tested?
Mazdutide versus placebo in US adults with overweight or obesity, excluding diabetes. ↗
Registered primary question: Percentage change in body weight at week 32. ↗
What the reviewed report found
Journal year 2026 · Article summary reviewed 2026-09-15
The reported hypothetical-estimand weight changes at week 32 were −7.3%, −15.6% and −18.1% versus −0.9%. Adverse events led to discontinuation in 20% of the highest active group.↗
Keep in context: The trial continued to week 48, but its primary weight endpoint was at week 32. Its hypothetical efficacy estimand and US population should remain distinct from the GLORY-1 report. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 179 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years to 75 Years
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2026-04-21; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
US phase 2 obesity trial
- Design in the report
- Randomized, placebo-controlled phase 2 trial with a week-32 primary endpoint and longer follow-up.↗
- Participants in the report
- 179 adults with overweight or obesity participated.↗
- Limitations
- A hypothetical estimand is not the same as observed outcomes regardless of discontinuation. Population, follow-up and estimand differences prevent direct comparison with GLORY-1.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight ↗
Protocol identifier: 18661. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 d0ae75ea6041b13d872f7113133b4e3280c8ef42504e8b51bab39c9fabea9d30.
PMID 42628555
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 42628555. SHA-256 7e3cd4cb35b2e5abb058fcf9f23f48e83e61e5ce248a821aa545ec71b48b435b.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 c0802aaae85a624375cf494b71908ffe9c67cce4c3c6a28f704ee56cdf0ac8f6.